2.13
+0.02(+0.95%)
Currency In USD
| Previous Close | 2.11 |
| Open | 2.06 |
| Day High | 2.13 |
| Day Low | 2.06 |
| 52-Week High | 9.79 |
| 52-Week Low | 0.97 |
| Volume | 18,310 |
| Average Volume | 972,162 |
| Market Cap | 10.22M |
| PE | -1.02 |
| EPS | -2.09 |
| Moving Average 50 Days | 2.26 |
| Moving Average 200 Days | 2.1 |
| Change | 0.02 |
If you invested $1000 in Phio Pharmaceuticals Corp. (PHIO) 10 years ago, it would be worth $0.01 as of September 18, 2025 at a share price of $2.13. Whereas If you bought $1000 worth of Phio Pharmaceuticals Corp. (PHIO) shares 5 years ago, it would be worth $7.64 as of September 18, 2025 at a share price of $2.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Phio Pharmaceuticals to Present at the Life Sciences Future Conference
Newsfile
3 hours ago
Key updates to include advances made in the on-going clinical trial for INTASYL siRNA lead product candidate PH-762King of Prussia, Pennsylvania--(Newsfile Corp. - September 18, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage bi
Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Newsfile
Sep 03, 2025 11:45 AM GMT
Clinical trial advances to anticipated final cohort for INSTASYL siRNA lead product candidate PH-7625th cohort patients now being treated in on-going clinical studyKing of Prussia, Pennsylvania--(Newsfile Corp. - September 3, 2025) - Phio Pharmaceuti
Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Newsfile
Aug 14, 2025 8:15 PM GMT
Clinical trial advances for INSTASYL siRNA lead product candidate PH-7625th cohort enrolling patients in on-going clinical studyKing of Prussia, Pennsylvania--(Newsfile Corp. - August 14, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinica